Chester County News and Community Website
PHILADELPHIA, PA — Medicus Pharma Ltd. is seeking U.S. Food and Drug Administration approval for a redesigned late-stage development plan that could cut enrollment in its Teverelix advanced prostate cancer …
Medicus Seeks FDA Path to Cut Teverelix Trial by 60% Read More
PLYMOUTH MEETING, PA — The National Comprehensive Cancer Network is funding four quality-improvement projects aimed at reducing gaps in metastatic prostate cancer care, targeting disparities in access, inconsistent testing and …
NCCN Funds Projects to Close Gaps in Prostate Cancer Care Read More
WILMINGTON, DE — AstraZeneca’s TRUQAP (capivasertib) has won U.S. approval for a subset of patients with advanced prostate cancer, providing the first biomarker-targeted treatment option for an aggressive form of …
FDA Clears AstraZeneca Prostate Cancer Therapy for PTEN Patients Read More PLYMOUTH MEETING, PA — National Comprehensive Cancer Network released a new patient guide on prostate cancer screening aimed at explaining current screening recommendations and addressing concerns about testing and treatment.
NCCN Releases Patient Guide on Prostate Cancer Screening Read More PLYMOUTH MEETING, PA — A study published in the February 2026 issue of JNCCN—Journal of the National Comprehensive Cancer Network found that incorporating prostate-specific membrane antigen PET/CT scans into evaluation …
Study Finds PSMA PET/CT Scans May Guide Treatment After Prostate Cancer Recurrence Read More
HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) reported new real-world evidence showing that patients with metastatic castration-sensitive prostate cancer who began treatment with ERLEADA without chemotherapy experienced a sharply …
Real-World Study Finds ERLEADA Cuts Death Risk in Advanced Prostate Cancer Read More HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) said the U.S. Food and Drug Administration has approved an expanded indication for AKEEGA, clearing the first FDA-approved precision medicine combination for …
FDA Clears Breakthrough Precision Combo for Aggressive Prostate Cancer Read More
WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the commercial launch of its Barrigel™ rectal spacer in Japan, marking a significant step in the company’s international expansion strategy. The …
Teleflex Launches Barrigel™ Rectal Spacer in Japan Following Regulatory Approval Read More PLYMOUTH MEETING, PA — New research published in the July 2025 issue of JNCCN—Journal of the National Comprehensive Cancer Network offers encouraging news for men diagnosed with nonmetastatic prostate cancer. …
Study Finds Most Prostate Cancer Patients Following NCCN Guidelines Live Long, Healthy Lives Read More WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has introduced two major initiatives during Men’s Health Month to highlight the challenges men face with benign prostatic hyperplasia (BPH) and the importance …
Teleflex Launches Awareness Initiatives for Men’s Health Month Read More